Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 037 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular osmolarity, acid-base balance, and normal nerve conduction and muscle contraction, including cardiac muscle. Dextrose provides a source of calories and may prevent ketosis.
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Intravenous infusion of potassium chloride 0.037% in dextrose 5% at a rate not exceeding 10 mEq/hour of potassium and a maximum concentration of 40 mEq/L in peripheral veins; dose determined by serum potassium level and clinical need, typically 20-40 mEq per day for mild depletion.
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
None Documented
None Documented
Potassium has a complex disposition; the distribution between intracellular and extracellular compartments affects half-life. In normal renal function, the serum potassium half-life is approximately 4-6 hours after a dose, but this is not a true terminal half-life due to extensive tissue buffering. The body's total potassium turnover half-life is around 25-30 hours. In patients with renal impairment, half-life is prolonged proportionally to creatinine clearance.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Potassium is primarily excreted renally (>90%) with about 10% excreted in feces via gastrointestinal secretion. Minimal excretion occurs through sweat. Renal handling involves glomerular filtration, proximal tubular reabsorption, and potassium secretion in the distal tubule and collecting duct regulated by aldosterone. Excretion is not linear and depends on potassium balance, renal function, and hormonal influences.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L).
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement